These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 16718700)

  • 1. Reply: GDNF poses troubling questions for doctors, drug maker.
    Slevin JT; Gerhardt GA; Smith CD; Gash DM; Young AB
    Ann Neurol; 2006 Jun; 59(6):989-90. PubMed ID: 16718700
    [No Abstract]   [Full Text] [Related]  

  • 2. GDNF poses troubling questions for doctors, drug maker. Toxicity, negative outcome raise doubts.
    Ann Neurol; 2006 Mar; 59(3):A5-6. PubMed ID: 16489612
    [No Abstract]   [Full Text] [Related]  

  • 3. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
    Lindvall O; Wahlberg LU
    Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuing trials of GDNF in Parkinson's disease.
    Barker RA
    Lancet Neurol; 2006 Apr; 5(4):285-6. PubMed ID: 16545740
    [No Abstract]   [Full Text] [Related]  

  • 5. GDNF in Parkinson disease: an object lesson in the tyranny of type II.
    Hutchinson M; Gurney S; Newson R
    J Neurosci Methods; 2007 Jul; 163(2):190-2. PubMed ID: 16876872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GDNF in treatment of Parkinson's disease: response to editorial.
    Lang AE; Langston JW; Stoessl AJ; Brodsky M; Brooks DJ; Dhawan V; Elias WJ; Lozano AM; Moro E; Nutt JG; Stacy M; Turner D; Wooten GF
    Lancet Neurol; 2006 Mar; 5(3):200-2. PubMed ID: 16488373
    [No Abstract]   [Full Text] [Related]  

  • 7. GDNF in treatment of Parkinson's disease: response to editorial.
    Penn RD; Dalvi A; Slevin J; Young B; Gash D; Gerhardt G; Hutchinson M
    Lancet Neurol; 2006 Mar; 5(3):202-3. PubMed ID: 16488374
    [No Abstract]   [Full Text] [Related]  

  • 8. GDNF therapy for Parkinson's disease.
    Hong M; Mukhida K; Mendez I
    Expert Rev Neurother; 2008 Jul; 8(7):1125-39. PubMed ID: 18590482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second chance.
    Check E
    Nat Med; 2007 Jul; 13(7):770-1. PubMed ID: 17618258
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats.
    Grandoso L; Ponce S; Manuel I; Arrúe A; Ruiz-Ortega JA; Ulibarri I; Orive G; Hernández RM; Rodríguez A; Rodríguez-Puertas R; Zumárraga M; Linazasoro G; Pedraz JL; Ugedo L
    Int J Pharm; 2007 Oct; 343(1-2):69-78. PubMed ID: 17583454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GDNF in Parkinson's disease: the perils of post-hoc power.
    Matcham J; McDermott MP; Lang AE
    J Neurosci Methods; 2007 Jul; 163(2):193-6. PubMed ID: 17540454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging restorative treatments for Parkinson's disease.
    Deierborg T; Soulet D; Roybon L; Hall V; Brundin P
    Prog Neurobiol; 2008 Aug; 85(4):407-32. PubMed ID: 18586376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
    Andereggen L; Meyer M; Guzman R; Ducray AD; Widmer HR
    Brain Res; 2009 Jun; 1276():39-49. PubMed ID: 19389387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson disease and growth factors - is GDNF good enough?
    Kirkeby A; Barker RA
    Nat Rev Neurol; 2019 Jun; 15(6):312-314. PubMed ID: 30948845
    [No Abstract]   [Full Text] [Related]  

  • 15. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
    Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
    Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glial cell line-derived neurotrophic factor added to a sciatic nerve fragment grafted in a spinal cord gap ameliorates motor impairments in rats and increases local axonal growth.
    Guzen FP; de Almeida Leme RJ; de Andrade MS; de Luca BA; Chadi G
    Restor Neurol Neurosci; 2009; 27(1):1-16. PubMed ID: 19164849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hard way to a Bill of Rights.
    Lancet Neurol; 2005 Dec; 4(12):787. PubMed ID: 16297831
    [No Abstract]   [Full Text] [Related]  

  • 18. Patients in test won't get drug, Amgen decides.
    Pollack A
    N Y Times Web; 2005 Feb; ():C1, C2. PubMed ID: 15742509
    [No Abstract]   [Full Text] [Related]  

  • 19. Exogenous administration of glial cell line-derived neurotrophic factor improves recovery after spinal cord injury.
    Kao CH; Chen SH; Chio CC; Chang CK; Lin MT
    Resuscitation; 2008 Jun; 77(3):395-400. PubMed ID: 18367307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuronal differentiation elicited by glial cell line-derived neurotrophic factor and ciliary neurotrophic factor in adrenal chromaffin cell line tsAM5D immortalized with temperature-sensitive SV40 T-antigen.
    Murata T; Tsuboi M; Koide N; Hikita K; Kohno S; Kaneda N
    J Neurosci Res; 2008 Jun; 86(8):1694-710. PubMed ID: 18293415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.